Get the Stockscreener App
1.52
7.32%
-0.12
After Hours:
1.50
-0.02
-1.32%
Entera Bio Ltd stock is traded at $1.52, with a volume of 197.58K.
It is down -7.32% in the last 24 hours and down -3.18% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.64
Open:
$1.64
24h Volume:
197.58K
Relative Volume:
1.06
Market Cap:
$69.70M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-4.4706
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
+29.91%
1M Performance:
-3.18%
6M Performance:
-19.58%
1Y Performance:
-36.13%
1-Day Range:
$1.4473
$1.66
1-Week Range:
$1.00
$1.66
52-Week Range:
$1.00
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.52 | 75.21M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Asianet Newsable
Insider Buying: Steven Rubin Acquires Shares of Entera Bio Ltd (ENTX) - GuruFocus
Sean Ellis Buys 18,000 Shares of Entera Bio (NASDAQ:ENTX) Stock - MarketBeat
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq
Entera Bio Ltd. Board Members and CEO Purchase Company Shares Amid Ongoing Development of Oral Therapies - Quiver Quantitative
Entera Bio insiders are buying more of their own shares on market - Stock Titan
Entera Bio appoints Geno Germano as board chairman By Investing.com - Investing.com South Africa
Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones - marketscreener.com
Entera Bio Ltd: Geno J. Germano appointed as chairman of Entera Bio - marketscreener.com
Entera Bio Ltd. Announces Board Changes - marketscreener.com
Entera Bio Attracts Former Pfizer Group President as It Enters a New Phase (NASDAQ: ENTX) - GuruFocus
Entera Bio appoints Geno Germano as board chairman - Investing.com
Entera Bio Names Geno Germano Independent Board Chairman - The Globe and Mail
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - The Manila Times
Entera Bio Ltd. Appoints Geno J. Germano as New Chairman of the Board as Company Advances Oral Peptide Pipeline - Quiver Quantitative
Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano - Longbridge
Aug Fed Impact: Can Entera Bio Ltd deliver consistent dividendsMarket Trend Review & Community Driven Trade Alerts - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Finviz
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Steven D. Rubin - Longbridge
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Stop Loss: Should I invest in Entera Bio Ltd before earningsJuly 2025 Rallies & Reliable Trade Execution Plans - baoquankhu1.vn
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio Ltd. Announces Board Changes, Effective February 1, 2026 - marketscreener.com
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Breakout Move: Can Entera Bio Ltd weather a recessionJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? - simplywall.st
Contrasting Entera Bio (NASDAQ:ENTX) and Barinthus Biotherapeutics (NASDAQ:BRNS) - Defense World
Is Entera Bio Ltd. on track to beat earnings2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Entera Bio Prepares For Key Q1 Milestones As EB613 Nears Phase 3 Transition - RTTNews
Investment Review: Can Launch One Acquisition Corp Debt Equity Composite Units weather a recessionGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Entera Bio plans FDA submission for osteoporosis drug in Q1 2026 - Investing.com Nigeria
Entera Bio Ltd. Announces Key Milestones and Upcoming FDA Submissions for EB613 and Oral Hypoparathyroidism Programs in Q1 2026 - Quiver Quantitative
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Sahm
Entera Bio (NASDAQ:ENTX) Trading Down 3.1%Here's Why - MarketBeat
Aug Levels: Is Entera Bio Ltd still a buy after recent gainsPortfolio Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
What margin trends mean for Entera Bio Ltd. stock2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Entera Bio Ltd. stock remain a Wall Street favoriteJuly 2025 Momentum & Technical Confirmation Alerts - Улправда
Is Entera Bio Ltd. stock oversold or undervalued2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
Is Entera Bio Ltd. (5DT) stock prepared for digital transitionRate Hike & Long-Term Capital Growth Ideas - Улправда
Entera Bio Ltd.Ordinary Shares (NQ: ENTX - FinancialContent
Breakout Watch: Can Entera Bio Ltd 5DT stock surprise with quarterly results2025 Technical Overview & Low Drawdown Momentum Ideas - moha.gov.vn
[Form 4] Entera Bio Ltd. Insider Trading Activity - Stock Titan
Entera Bio Ltd. (NASDAQ: ENTX) director reports 2026 share and option grants - Stock Titan
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):